ORGANOGENESIS HOLDINGS INC. Taxes Payable, Current
ORGANOGENESIS HOLDINGS INC. (ORGO) had Taxes Payable, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:TaxesPayableCurrent · last filed 2026-02-26
- 2025-12-31: Taxes Payable, Current $0.00.
- 2025-09-30: Taxes Payable, Current $176.00K.
- 2025-06-30: Taxes Payable, Current $175.00K.
- 2025-03-31: Taxes Payable, Current $175.00K.
| Period end | Taxes Payable, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $176.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $175.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $175.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $4.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | $166.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $3.88M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $483.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | $6.18M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.70M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $771.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $2.63M 10-K · filed 2024-02-29 |
| 2021-12-31 | $1.16M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |